HBT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HBT Financial is not a strong buy right now for a beginner long-term investor with $50,000-$100,000, but it is a reasonable hold/watch candidate. The stock has supportive technicals and a slightly constructive pre-market setup, yet the lack of fresh news, the absence of a bullish proprietary signal, and neutral insider/hedge fund activity keep the upside case from being compelling enough for an immediate buy.
Technically, HBT is in an uptrend. SMA_5 is above SMA_20 and SMA_200, which is bullish. The MACD histogram is positive at 0.107, though it is contracting, suggesting momentum is still positive but not accelerating. RSI_6 at 63.385 is neutral-to-mildly bullish and not overbought. Price at 28.61 is just below R1 at 28.855 and above the pivot at 28.037, indicating the stock is trading near short-term resistance after a recent run. The trend model also suggests modest near-term upside, with a 70% chance of a small gain over the next day, week, and month.
["Bullish moving average structure: SMA_5 > SMA_20 > SMA_200.", "MACD remains above zero, supporting the current uptrend.", "Analysts have raised price targets recently, with Keefe Bruyette at $33 and Piper Sandler at $32.", "Analyst commentary remains constructive on profitability and acquisition benefits.", "Pre-market price is near the upper end of the recent technical range, showing continued demand."]
["No news in the recent week, so there is no fresh catalyst driving the stock.", "No AI Stock Picker signal today and no recent SwingMax signal.", "Options open interest put-call ratio of 2.61 shows bearish positioning.", "Hedge funds and insiders are both neutral with no significant recent buying trend.", "Piper Sandler keeps only a Neutral rating, which limits conviction."]
No usable latest-quarter financial snapshot was provided because the financial data returned an error. Based on analyst commentary, Q1 results were described as noisy due to the CNBN acquisition closing on March 2, but PPNR was essentially in-line and core profitability remained well above average. Management also gave a more conservative low-single-digit loan growth outlook, which suggests steady but not aggressive growth. The latest quarter season referenced in analyst coverage is Q1 2026.
Recent analyst trend is mildly positive on price targets but mixed on stance. Keefe Bruyette raised its target to $33 and kept an Outperform rating. Piper Sandler raised its target to $32 from $30, but kept a Neutral rating, while noting solid core profitability and in-line pre-provision net revenue. Earlier in March, Piper Sandler also raised its target to $30 from $29 while remaining Neutral, citing benefits from the CNBN acquisition. Wall Street’s view is balanced: the pros see acquisition-driven EPS accretion and strong profitability, while the cons are slower loan growth expectations and only moderate conviction from the Neutral rating.
